ArticleMolecular cancer therapeutics2019

First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Anna Capasso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.